Not applicableNot Yet RecruitingNCT07644754
What this trial is testing
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases
Who this might be right for
Prostate CancerProstate Cancer Metastatic DiseaseProstate Cancer Metastatic to Bone
University Hospital Tuebingen 27